{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:11:34Z","timestamp":1765483894474},"reference-count":15,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T00:00:00Z","timestamp":1376870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Gliptins are new oral antidiabetic drugs that increase insulin levels through dipeptidyl peptidase\u20104 inhibition. Recently, the association of serious musculoskeletal (MSk) adverse effects with the gliptin use has been suggested. The aim is to describe and analyze the characteristics of spontaneous reports related to these adverse effects and gliptin use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All spontaneous reports with MSk disorders associated with gliptins gathered in the Spanish pharmacovigilance database until May 2012 were described and analyzed using a case\/non\u2010case method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Gliptins were reported as the suspected drug in 332 cases: 208 involved sitagliptin, 115 vildagliptin, and nine saxagliptin. In 34 patients (10.2% of total reports with gliptins), MSk reactions were described (22 women [64.7%] and 12 men [35.3%]). Their mean age was 65.1\u2009years; 41.2% were younger than 65\u2009years. Only seven cases were serious, but the gliptin had to be withdrawn in 22 patients because of intolerance and\/or persistence of MSk discomfort, and patients recovered after its discontinuation. A positive re\u2010challenge was observed in two cases. In seven cases, the patients were on previous chronic treatment with statins, and began to present MSk complaints shortly after starting a gliptin. The reporting odds ratio (ROR) for myalgia and arthralgia were strongly associated with gliptin use (ROR 1.96 [95% CI 1.12\u20133.43], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 and ROR 2.69 [95% CI 1.38\u20135.24], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Musculoskeletal disorders are adverse reactions strongly associated with gliptins that, despite not being serious, may impair the treatment adherence in patients with type 2 diabetes. Future observational studies could confirm these findings. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3503","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T12:58:44Z","timestamp":1376917124000},"page":"1115-1118","source":"Crossref","is-referenced-by-count":35,"title":["Association of musculoskeletal complaints and gliptin use: review of spontaneous reports"],"prefix":"10.1002","volume":"22","author":[{"given":"M\u00f3nica","family":"Tarapu\u00e9s","sequence":"first","affiliation":[{"name":"Pharmacology, Therapeutics and Toxicology Department Universitat Aut\u00f2noma de Barcelona  Bellaterra (Cerdanyola del Vall\u00e8s) Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Cereza","sequence":"additional","affiliation":[{"name":"Pharmacology, Therapeutics and Toxicology Department Universitat Aut\u00f2noma de Barcelona  Bellaterra (Cerdanyola del Vall\u00e8s) Spain"},{"name":"Fundaci\u00f3 Institut Catal\u00e0 de Farmacologia Passeig Vall d'Hebron  Barcelona Spain"},{"name":"Catalan Centre of Pharmacovigilance  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Figueras","sequence":"additional","affiliation":[{"name":"Pharmacology, Therapeutics and Toxicology Department Universitat Aut\u00f2noma de Barcelona  Bellaterra (Cerdanyola del Vall\u00e8s) Spain"},{"name":"Fundaci\u00f3 Institut Catal\u00e0 de Farmacologia Passeig Vall d'Hebron  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.028"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1771"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03502.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02536.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1995"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.3.352"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_7_9_1","unstructured":"European Medicines Agency.Summary of product characteristics Januvia\u00ae. Update 24\/09\/2012http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000722\/WC500039054.pdf[29 October 2012]."},{"key":"e_1_2_7_10_1","unstructured":"Food and Drug Administration.Summary of product characteristics Januvia\u00ae. Update 18\/10\/2012 hhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021995s025lbl.pdf[29 October 2012]."},{"key":"e_1_2_7_11_1","unstructured":"Netherlands Pharmacovigilance Centre Lareb.An overview of reports on sitagliptin.[Internet] 2011.http:\/\/www.lareb.nl\/LarebCorporateWebsite\/media\/publicaties\/kwb_2011_1_sitag.pdf[1 May 2012]."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62266-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010817"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.0091"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2005.08.003"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008330983"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3503","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T19:10:48Z","timestamp":1697483448000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,19]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1002\/pds.3503"],"URL":"https:\/\/doi.org\/10.1002\/pds.3503","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,19]]}}}